IceCure Medical Ltd. (Nasdaq: ICCM) reported that U.S. revenue from its ProSense cryoablation system and cryoprobes rose more than 30% in the first quarter of 2026 compared with the $725,000 reported for the same period in 2025, according to preliminary, unaudited estimates.
The growth follows the October 2025 FDA clearance of ProSense for low‑risk early‑stage breast cancer in women aged 70 and older, and the company’s active participation in the Society of Breast Imaging 2026 Symposium in Seattle (April 16‑19). The clearance opened a new patient segment, while the symposium provided hands‑on training and increased physician awareness, both of which contributed to the uptick in sales.
IceCure expects to close new system sales in the second quarter of 2026, expanding its installed base at leading academic and research hospitals. The company will release its full first‑quarter 2026 operating and financial results on May 14 2026, which will provide a more detailed view of revenue, margins, and guidance.
The 30%+ increase signals accelerating commercial adoption of the liquid‑nitrogen cryoablation platform and validates the company’s strategy to capture the U.S. breast‑cancer market. The company is pursuing CPT III reimbursement for the procedure and is preparing to submit for CPT I coverage, while a post‑market study approved by the FDA will enroll approximately 400 patients across 30 U.S. sites to further demonstrate clinical and economic value.
While the preliminary nature of the figures means they are subject to final adjustments, the announcement reflects a clear tailwind from regulatory approval and physician engagement, and positions IceCure to build momentum in the coming quarters.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.